Is This the Right Time to Retain Omnicell Stock in Your Portfolio?
OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
OMCL - Omnicell, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$56.67
DETAILS
HIGH:
$65.00
LOW:
$50.00
MEDIAN:
$55.00
CONSENSUS:
$56.67
UPSIDE:
50.12%
Stock News
Financial Contrast: Baxter International (NYSE:BAX) and Omnicell (NASDAQ:OMCL)
Omnicell (NASDAQ: OMCL - Get Free Report) and Baxter International (NYSE: BAX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of recent ratings
Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.
Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Omnicell (OMCL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations
Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.
Why Omnicell (OMCL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Omnicell President Sells 6,753 Shares
The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.
Bank of America Corp DE Has $19.39 Million Position in Omnicell, Inc. $OMCL
Bank of America Corp DE raised its holdings in Omnicell, Inc. (NASDAQ: OMCL) by 31.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 580,875 shares of the company's stock after acquiring an additional 138,537 shares during the
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins
OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build
Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.
Here's Why Omnicell (OMCL) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Omnicell Inc (OMCL) a Bargain After 4.7% Drop? GF Value Says Undervalued
On July 31, 2026, Omnicell Inc (OMCL) shares fell 4.7% today, bringing the current price to $35.37. The stock has experienced significant fluctuations over the
OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growth
Omnicell highlights Titan XT and OmniSphere momentum, and raises profit outlook, while customer approval timing weighs on product bookings.
Dimensional Fund Advisors LP Acquires 137,834 Shares of Omnicell, Inc. $OMCL
Dimensional Fund Advisors LP raised its holdings in Omnicell, Inc. (NASDAQ: OMCL) by 6.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,450,385 shares of the company's stock after purchasing an additional 137,834 shares during the period. Dimensional Fund Advisors LP
EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
FORT WORTH, Texas--(BUSINESS WIRE)--EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination.
Omnicell Q2 Earnings Call Highlights
Omnicell NASDAQ: OMCL reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform investments.
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcript
Omnicell (OMCL) Q2 Earnings and Revenues Top Estimates
Omnicell (OMCL) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.
Price Targets
Omnicell price target lowered to $65 from $70 at KeyBanc
$65.00
(was $37.11)
KeyBanc
Omnicell price target lowered to $50 from $55 at Wells Fargo
$50.00
(was $37.11)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target raised to $55 from $53 at Craig-Hallum
$55.00
(was $44.45)
Craig-Hallum
Omnicell price target raised to $70 from $60 at KeyBanc
$70.00
(was $44.31)
KeyBanc
Omnicell (OMCL) Reiterated at Buy by Benchmark After Investor, CEO Meet
$60.00
(was $35.10)
UBS
Omnicell price target lowered to $49 from $63 at Piper Sandler
$49.00
(was $39.08)
Piper Sandler
Omnicell (OMCL) PT Raised to $53 at BofA Securities
$53.00
(was $50.98)
UBS
Omnicell upgraded to Overweight from Sector Weight at KeyBanc
$60.00
(was $47.45)
KeyBanc
Omnicell price target raised to $52 from $43 at Wells Fargo
$52.00
(was $45.64)
Wells Fargo
Omnicell (OMCL) PT Lowered to $55 at Piper Sandler Despite Guide Raise
$55.00
(was $31.11)
Jessica Tassan
·
Piper Sandler
Omnicell upgraded to Overweight from Equal Weight at Wells Fargo
$35.00
(was $27.46)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target lowered to $40 from $49 at Wells Fargo
$40.00
(was $43.37)
Stan Berenshteyn
·
Wells Fargo
Omnicell price target raised to $58 from $39 at Barclays
$58.00
(was $53.05)
Stephanie Davis
·
Barclays
Omnicell (OMCL) PT Raised to $61 at Piper Sandler
$61.00
(was $40.00)
Sean Wieland
·
Piper Sandler
Barclays Upgrades Omnicell (OMCL) to Equalweight
$39.00
(was $39.22)
Stephanie Davis
·
Barclays
JP Morgan Maintains Neutral on Omnicell, Lowers Price Target to $57
$57.00
(was $53.63)
J.P. Morgan
Omnicell price target lowered to $150 from $162 at Piper Sandler
$150.00
(was $109.12)
Jessica Tassan
·
Piper Sandler
Samsung procurement order halt 'positive' for Omnicell, says Wells Fargo
$158.00
(was $109.82)
Stan Berenshteyn
·
Wells Fargo
Piper Sandler Maintains Overweight on Omnicell, Lowers Price Target to $162
$162.00
(was $114.90)
Piper Sandler